Navigation Links
XTENT Announces 2007 Financial Results Conference Call
Date:2/12/2008

MENLO PARK, Calif., Feb. 12 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) announced that it will report its financial results for 2007 after market close on Tuesday, February 19, 2008. The company will hold a conference call the same day at 2 p.m., Pacific Time (5 p.m. Eastern Time). The call will be hosted by Gregory D. Casciaro, XTENT's President and Chief Executive Officer, and Tim Kahlenberg, Chief Financial Officer.

The teleconference can be accessed via the investor relations section of the company's website at http://investor.xtentinc.com/events.cfm or by calling 877-627-6580 (domestic), 719-325-4903 (international). Please dial in or access the website 5 to 10 minutes prior to the beginning of the call.

An online archive of the webcast will be available for a minimum of three months by accessing the investor relations portion of the company's website at http://investor.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.


'/>"/>
SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
2. XTENT Announces Third Quarter 2007 Financial Results
3. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
4. USHEALTH Group Announces Appointment of Executive Vice President
5. Perrigo Company Announces Final FDA Approval for OTC Famotidine Complete Chewable Tablets
6. Herley Industries Announces the Passing of Its Former President
7. GPhA Announces 2008-2009 Executive Committee; Teva North Americas Bill Marth Elected as Chairman of the Board
8. Asoyia Announces New Mid Oleic Ultra Low Lin Soybean Oil
9. Methodist Healthcare - Memphis Hospitals Announces the Commencement of the Tender Offer for Certain Designated Maturities of:
10. Isis Announces Approximately $2.8 Million in Government Grants and Contracts Awarded to its Ibis Subsidiary to Advance Ibis Pathogen Identification Technology
11. Sosei Announces Start of AD 923 Phase III Studies in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has ... personnel have a basic understanding of the techniques they use so they can ... help them reduce waste and rework to create a leaner overall lab experience. ...
(Date:2/9/2016)... ... 09, 2016 , ... United Methodist Communications collaborated with Chocolate ... animated video designed to prevent the next widespread Ebola outbreak from ... being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African ...
(Date:2/9/2016)... ... 09, 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers of ... GRIP-DRY is a newly patented product that has solved some of the basic problems golfers ... early morning dew or right after a rain shower, might understand the struggle of placing ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Federal ... federallabs.org . The site houses a wealth of federal resources that businesses ... the process called technology transfer (T2). As a network of over 300 federal ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Houma, LA, celebrates the beginning of a new charity campaign. As part of ... Appointed Special Advocates (CASA). In the belief that children deserve a voice, and ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... Feb. 9, 2016 The new report "Global Diagnostic Ultrasound ... & Consulting group reveals that global diagnostic ultrasound devices market was ... to US$ 7,466.3 million by 2019 at a CAGR of 6.8% ... global ultrasound market has been analyzed for six geographies of ... Asia-Pacific , Latin America , ...
(Date:2/9/2016)... , Feb. 9, 2016 The leader ... that AcceleDent ® is the recipient of the ... category. An FDA-cleared, Class II medical device that speeds ... percent and relieves pain often associated with treatment, AcceleDent ... participated in the annual Orthotown survey of ...
Breaking Medicine Technology: